Search

Your search keyword '"Tondini, Carlo Alberto"' showing total 22 results
Start Over Author "Tondini, Carlo Alberto"
22 results on '"Tondini, Carlo Alberto"'

1. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies

Author

Miglietta, Federica, Dieci, Maria Vittoria, Giarratano, Tommaso, Torri, Valter, Giuliano, Mario, Zustovich, Fable, Mion, Marta, Tondini, Carlo Alberto, De Rossi, Costanza, Bria, Emilio, Franchi, Michela, Merlini, Laura, Giannatiempo, Rosa, Russo, Daniela, Fotia, Vittoria, Poletti, Paola, Caremoli, Elena Rota, Arpino, Maria Grazia, De Salvo, Gian Luca, Zambelli, Alberto, and Guarneri, Valentina

Published
2023
Full Text
View/download PDF

2. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Author

Anpalakhan, Shobana, Signori, Alessio, Cortellini, Alessio, Verzoni, Elena, Giusti, Raffaele, Aprile, Giuseppe, Ermacora, Paola, Catino, Annamaria, Pipitone, Stefania, Di Napoli, Marilena, Scotti, Vieri, Mazzoni, Francesca, Guglielmini, Pamela F., Veccia, Antonello, Maruzzo, Marco, Schinzari, Giovanni, Casadei, Chiara, Grossi, Francesco, Rizzo, Mimma, Montesarchio, Vincenzo, Verderame, Francesco, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Tondini, Carlo Alberto, Camerini, Andrea, Banzi, Maria Chiara, Sorarù, Mariella, Zucali, Paolo Andrea, Vignani, Francesca, Ricciardi, Serena, Russo, Antonio, Cosenza, Agnese, Di Maio, Massimo, De Giorgi, Ugo, Pignata, Sandro, Giannarelli, Diana, Pinto, Carmine, Buti, Sebastiano, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Rescigno, Pasquale, Addeo, Alfredo, Banna, Giuseppe L., and Bersanelli, Melissa

Published
2023
Full Text
View/download PDF

3. A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial

Author

Passardi, Alessandro, primary, Foca, Flavia, additional, Caffo, Orazio, additional, Tondini, Carlo Alberto, additional, Zambelli, Alberto, additional, Vespignani, Roberto, additional, Bartolini, Giulia, additional, Sullo, Francesco Giulio, additional, Andreis, Daniele, additional, Dianti, Marco, additional, Eccher, Claudio, additional, Piras, Enrico Maria, additional, and Forti, Stefano, additional

Published
2022
Full Text
View/download PDF

4. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Author

Dettorre, Gino M., Dolly, Saoirse, Loizidou, Angela, Chester, John, Jackson, Amanda, Mukherjee, Uma, Zambelli, Alberto, Aguilar Company, Juan, Bower, Mark, Sng, Christopher C. T., Salazar Soler, Ramón, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Seeva, Pavetha, Rizzo, Gianpiero, Libertini, Michela, Maconi, Antonio, Moss, Charlotte, Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona García, M. Carmen, Chopra, Neha, Tondini, Carlo Alberto, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi González, Nadia, Felip, Eudald, Roqué, Ariadna, Lee, Alvin J. X., Newsom-Davis, Tom, García Illescas, David, Reyes, Roxana, Wong, Yien Ning Sophia, Ferrante, Daniela, Scotti, Lorenza, Marco Hernández, Javier, Ruiz Camps, Isabel, Patriarca, Andrea, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Santoro, Armando, Prat Aparicio, Aleix, Gennari, Alessandra, Van Hemelrijck, Mieke, Tabernero Caturla, Josep, Diamantis, Nikolaos, Pinato, David J., OnCovid study group, Dettorre, G. M., Dolly, S., Loizidou, A., Chester, J., Jackson, A., Mukherjee, U., Zambelli, A., Aguilar-Company, J., Bower, M., Sng, C. C. T., Salazar, R., Bertuzzi, A., Brunet, J., Mesia, R., Sita-Lumsden, A., Segui, E., Biello, F., Generali, D., Grisanti, S., Seeva, P., Rizzo, G., Libertini, M., Maconi, A., Moss, C., Russell, B., Harbeck, N., Vincenzi, B., Bertulli, R., Ottaviani, D., Linan, R., Marrari, A., Carmen Carmona-Garcia, M., Chopra, N., Tondini, C. A., Mirallas, O., Tovazzi, V., Fotia, V., Cruz, C. A., Saoudi-Gonzalez, N., Felip, E., Roque, A., Lee, A. J. X., Newsom-Davis, T., Garcia-Illescas, D., Reyes, R., Wong, Y. N. S., Ferrante, D., Scotti, L., Marco-Hernandez, J., Ruiz-Camps, I., Patriarca, A., Rimassa, L., Chiudinelli, L., Franchi, M., Santoro, A., Prat, A., Gennari, A., Van Hemelrijck, M., Tabernero, J., Diamantis, N., Pinato, D. J., Wellcome Trust, Institut Català de la Salut, [Dettorre GM] Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. [Dolly S] Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust (GSTT), London, UK. [Loizidou A] Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. [Chester J] Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK. Medical Oncology, Velindre Cancer Centre, Cardiff, UK. [Jackson A] Clinical Trials, Velindre Cancer Centre, Cardiff, UK. [Mukherjee U] Medical Oncology, Barts Health NHS Trust, London, UK. [Aguilar-Company J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Mirallas O, Saoudi-Gonzalez N, García-Illescas D] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, Comorbidity, Systemic inflammation, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], COVID-19 Testing, 0302 clinical medicine, Neoplasms, Immunotherapy Biomarkers, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], 80 and over, Immunology and Allergy, Medicine, Hypoalbuminemia, Young adult, Càncer, Multivariate Analysi, RC254-282, COVID-19 (Malaltia) - Complicacions, Cancer, Aged, 80 and over, OnCovid study group, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Middle Aged, Prognosis, Inflamació, Systemic Inflammatory Response Syndrome, 030220 oncology & carcinogenesis, Cohort, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome [DISEASES], Molecular Medicine, Female, medicine.symptom, Life Sciences & Biomedicine, Human, Adult, medicine.medical_specialty, Prognosi, Càncer - Epidemiologia, Immunology, neoplasias [ENFERMEDADES], inflammation mediator, Young Adult, 03 medical and health sciences, Internal medicine, Humans, afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica [ENFERMEDADES], Aged, Pharmacology, Science & Technology, business.industry, SARS-CoV-2, COVID-19, medicine.disease, inflammation, inflammation mediators, Blood Cell Count, Multivariate Analysis, Neoplasms [DISEASES], Systemic inflammatory response syndrome, 030104 developmental biology, Neoplasm, Lymphocytopenia, business, Other subheadings::Other subheadings::/complications [Other subheadings]
Abstract

Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamació; Mediadors d'inflamació Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamación; Mediadores de la inflamación Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammation; Inflammation mediators Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study. Methods In a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets. Results We evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p

Published
2021

5. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Rogiers, Aljosja, Pires da Silva, Ines, Tentori, Chiara, Tondini, Carlo Alberto, Grimes, Joseph M, Trager, Megan H, Nahm, Sharon, Zubiri, Leyre, Manos, Michael, Bowling, Peter, Elkrief, Arielle, Papneja, Neha, Vitale, Maria Grazia, Rose, April A N, Borgers, Jessica S W, Roy, Severine, Mangana, Joanna, Pimentel Muniz, Thiago, Cooksley, Tim, Lupu, Jeremy, Vaisman, Alon, Saibil, Samuel D, Butler, Marcus O, Menzies, Alexander M, Carlino, Matteo S, Erdmann, Michael, Berking, Carola, Zimmer, Lisa, Schadendorf, Dirk, Pala, Laura, Queirolo, Paola, Posch, Christian, Hauschild, Axel, Dummer, Reinhard, Haanen, John, Blank, Christian U, Robert, Caroline, Sullivan, Ryan J, Ascierto, Paolo Antonio, Miller, Wilson H, Stephen Hodi, F, Suijkerbuijk, Karijn P M, Reynolds, Kerry L, Rahma, Osama E, Lorigan, Paul C, Carvajal, Richard D, Lo, Serigne, Mandala, Mario, Long, Georgina V, MS Medische Oncologie, Infection & Immunity, Cancer, Rogiers, Aljosja, Pires da Silva, Ines, Tentori, Chiara, Tondini, Carlo Alberto, Grimes, Joseph M, Trager, Megan H, Nahm, Sharon, Zubiri, Leyre, Manos, Michael, Bowling, Peter, Elkrief, Arielle, Papneja, Neha, Vitale, Maria Grazia, Rose, April A N, Borgers, Jessica S W, Roy, Severine, Mangana, Joanna, Pimentel Muniz, Thiago, Cooksley, Tim, Lupu, Jeremy, Vaisman, Alon, Saibil, Samuel D, Butler, Marcus O, Menzies, Alexander M, Carlino, Matteo S, Erdmann, Michael, Berking, Carola, Zimmer, Lisa, Schadendorf, Dirk, Pala, Laura, Queirolo, Paola, Posch, Christian, Hauschild, Axel, Dummer, Reinhard, Haanen, John, Blank, Christian U, Robert, Caroline, Sullivan, Ryan J, Ascierto, Paolo Antonio, Miller, Wilson H, Stephen Hodi, F, Suijkerbuijk, Karijn P M, Reynolds, Kerry L, Rahma, Osama E, Lorigan, Paul C, Carvajal, Richard D, Lo, Serigne, Mandala, Mario, and Long, Georgina V

Published
2021

8. Multigene tests for breast cancer: the physician’s perspective

Author

Cognetti, Francesco, primary, Biganzoli, Laura, additional, De Placido, Sabino, additional, Mastro, Lucia del, additional, Masetti, Riccardo, additional, Naso, Giuseppe, additional, Pruneri, Giancarlo, additional, Santini, Donatella, additional, Tondini, Carlo Alberto, additional, Tinterri, Corrado, additional, Tonini, Giuseppe, additional, and Barni, Sandro, additional

Published
2021
Full Text
View/download PDF

9. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Author

Dettorre, Gino M, primary, Dolly, Saoirse, additional, Loizidou, Angela, additional, Chester, John, additional, Jackson, Amanda, additional, Mukherjee, Uma, additional, Zambelli, Alberto, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Sng, Christopher C T, additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Mesia, Ricard, additional, Sita-Lumsden, Ailsa, additional, Seguí, Elia, additional, Biello, Federica, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Seeva, Pavetha, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Maconi, Antonio, additional, Moss, Charlotte, additional, Russell, Beth, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Bertulli, Rossella, additional, Ottaviani, Diego, additional, Liñan, Raquel, additional, Marrari, Andrea, additional, Carmona-García, M Carmen, additional, Chopra, Neha, additional, Tondini, Carlo Alberto, additional, Mirallas, Oriol, additional, Tovazzi, Valeria, additional, Fotia, Vittoria, additional, Cruz, Claudia Andrea, additional, Saoudi-Gonzalez, Nadia, additional, Felip, Eudald, additional, Roqué, Ariadna, additional, Lee, Alvin J X, additional, Newsom-Davis, Tom, additional, García-Illescas, David, additional, Reyes, Roxana, additional, Wong, Yien Ning Sophia, additional, Ferrante, Daniela, additional, Scotti, Lorenza, additional, Marco-Hernández, Javier, additional, Ruiz-Camps, Isabel, additional, Patriarca, Andrea, additional, Rimassa, Lorenza, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Santoro, Armando, additional, Prat, Aleix, additional, Gennari, Alessandra, additional, Van Hemelrijck, Mieke, additional, Tabernero, Josep, additional, Diamantis, Nikolaos, additional, and Pinato, David J, additional

Published
2021
Full Text
View/download PDF

10. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Author

Mandala, Mario, primary, Lorigan, Paul, additional, De Luca, Matilde, additional, Bianchetti, Andrea, additional, Merelli, Barbara, additional, Bettini, Anna Cecilia, additional, Bonomi, Lucia, additional, Nahm, Sharon, additional, Vitale, Maria Grazia, additional, Negrini, Giorgia, additional, Di Croce, Andrea, additional, Ascierto, Paolo Antonio, additional, Rulli, Eliana, additional, and Tondini, Carlo Alberto, additional

Published
2021
Full Text
View/download PDF

11. A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial (Preprint)

Author

Passardi, Alessandro, primary, Foca, Flavia, additional, Caffo, Orazio, additional, Tondini, Carlo Alberto, additional, Zambelli, Alberto, additional, Vespignani, Roberto, additional, Bartolini, Giulia, additional, Sullo, Francesco Giulio, additional, Andreis, Daniele, additional, Dianti, Marco, additional, Eccher, Claudio, additional, Piras, Enrico Maria, additional, and Forti, Stefano, additional

Published
2021
Full Text
View/download PDF

12. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Author

Rogiers, Aljosja, primary, Pires da Silva, Ines, additional, Tentori, Chiara, additional, Tondini, Carlo Alberto, additional, Grimes, Joseph M, additional, Trager, Megan H, additional, Nahm, Sharon, additional, Zubiri, Leyre, additional, Manos, Michael, additional, Bowling, Peter, additional, Elkrief, Arielle, additional, Papneja, Neha, additional, Vitale, Maria Grazia, additional, Rose, April A N, additional, Borgers, Jessica S W, additional, Roy, Severine, additional, Mangana, Joanna, additional, Pimentel Muniz, Thiago, additional, Cooksley, Tim, additional, Lupu, Jeremy, additional, Vaisman, Alon, additional, Saibil, Samuel D, additional, Butler, Marcus O, additional, Menzies, Alexander M, additional, Carlino, Matteo S, additional, Erdmann, Michael, additional, Berking, Carola, additional, Zimmer, Lisa, additional, Schadendorf, Dirk, additional, Pala, Laura, additional, Queirolo, Paola, additional, Posch, Christian, additional, Hauschild, Axel, additional, Dummer, Reinhard, additional, Haanen, John, additional, Blank, Christian U, additional, Robert, Caroline, additional, Sullivan, Ryan J, additional, Ascierto, Paolo Antonio, additional, Miller Jr, Wilson H, additional, Stephen Hodi, F, additional, Suijkerbuijk, Karijn P M, additional, Reynolds, Kerry L, additional, Rahma, Osama E, additional, Lorigan, Paul C, additional, Carvajal, Richard D, additional, Lo, Serigne, additional, Mandala, Mario, additional, and Long, Georgina V, additional

Published
2021
Full Text
View/download PDF

13. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review

Author

Airoldi, Mario, Amadori, Dino, Barni, Sandro, Cinieri, Saverio, De Placido, Sabino, Di Leo, Angelo, Gennari, Alessandra, Iacobelli, Stefano, Ionta, Maria Teresa, Lorusso, Vito, Lotrionte, Marzia, Marchetti, Paolo, Mattioli, Rodolfo, Minotti, Giorgio, Pronzato, Paolo, Rosti, Giovanni, Tondini, Carlo Alberto, and Veronesi, Andrea

Published
2011
Full Text
View/download PDF

14. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Author

Rutkowski, Piotr, primary, Indini, Alice, additional, De Luca, Matilde, additional, Merelli, Barbara, additional, Mariuk-Jarema, Anna, additional, Teterycz, Pawel, additional, Rogala, Pawel, additional, Lugowska, Iwona, additional, Cybulska-Stopa, Bożena, additional, Labianca, Alice, additional, Di Guardo, Lorenza, additional, Del Vecchio, Michele, additional, Pigozzo, Jacopo, additional, Randon, Giovanni, additional, Corti, Francesca, additional, Tondini, Carlo Alberto, additional, Rulli, Eliana, additional, and Mandala, Mario, additional

Published
2020
Full Text
View/download PDF

15. Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study

Author

Kümmel, Sherko, primary, Tondini, Carlo Alberto, additional, Abraham, Jacinta, additional, Nowecki, Zbigniew, additional, Itrych, Bartosz, additional, Hitre, Erika, additional, Karaszewska, Bogusława, additional, Juárez-Ramiro, Alejandro, additional, Morales-Vásquez, Flavia, additional, García, Jose Manuel Pérez, additional, Cardona-Huerta, Servando, additional, Monturus, Estefania, additional, Sequi, Marco, additional, Restuccia, Eleonora, additional, Benyunes, Mark, additional, and Martín, Miguel, additional

Published
2020
Full Text
View/download PDF

17. Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.

Author

Conte, Pier Franco, primary, Dieci, Maria Vittoria, additional, Bisagni, Giancarlo, additional, De Laurentiis, Michelino, additional, Tondini, Carlo Alberto, additional, Schmid, Peter, additional, De Salvo, Gian Luca, additional, Moratello, Giacomo, additional, and Guarneri, Valentina, additional

Published
2020
Full Text
View/download PDF

19. Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity

Author

Frassoldati, Antonio, primary, Biganzoli, Laura, additional, Bordonaro, Roberto, additional, Cinieri, Saverio, additional, Conte, Pierfranco, additional, Laurentis, Michelino De, additional, Mastro, Lucia Del, additional, Gori, Stefania, additional, Lauria, Rossella, additional, Marchetti, Paolo, additional, Michelotti, Andrea, additional, Montemurro, Filippo, additional, Naso, Giuseppe, additional, Pronzato, Paolo, additional, Puglisi, Fabio, additional, and Tondini, Carlo Alberto, additional

Published
2020
Full Text
View/download PDF

21. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.

Author

Regan, Meredith M., primary, Francis, Prudence A., additional, Pagani, Olivia, additional, Fleming, Gini F., additional, Walley, Barbara, additional, Viale, Giuseppe, additional, Colleoni, Marco, additional, Lang, Istvan, additional, Gomez, Henry Leonidas, additional, Tondini, Carlo Alberto, additional, Pinotti, Graziella, additional, Di Leo, Angelo, additional, Coates, Alan S., additional, Goldhirsch, Aron, additional, and Gelber, Richard D., additional

Published
2018
Full Text
View/download PDF

22. The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model

Author

Pruneri, Giancarlo and Tondini, Carlo Alberto

Abstract

Background: The accurate identification of patients with early breast cancer (eBC) suitable for adjuvant chemotherapy is essential in order to avoid overtreatment or undertreatment. For eBC patients with luminal (HR+/HER2−) intermediate risk disease, multigene assays (MGAs) have been convincingly reported to be useful in guiding treatment decisions. The most recently published data and recommendations from main International Guidelines and Heath Technology Assessment reports confirmed the benefit of MGAs in guiding treatment decisions for clinically intermediate risk patients, and led several countries to test reimbursement.Purpose: This article describes the process followed by the Lombardy region in Italy regarding the reimbursement of MGAs for patients with eBC, based on the results of a prospective clinical trial.Results: The study shows that the use of Oncotype DX allowed avoiding the use of unnecessary adjuvant chemotherapy in 50% of patients for whom chemotherapy was initially recommended according to traditional clinical practice. On the basis of these data, a group of oncologists in collaboration with a pathologist regional board formally requested authorization for MGA reimbursement in Lombardy. Acknowledging the strategic importance of the proposal, the Lombardy region approved the reimbursement of MGAs for resident patients with luminal eBC at intermediate clinical risk. It can be assumed that about 1500 patients will be tested in Lombardy per year and this should allow the Regional Health Service to save more than 750 chemotherapies/year.Conclusion: The introduction of MGAs in the clinical evaluation of patients with luminal eBC with intermediate risk is economically sustainable and contributes towards preserving quality of life of eligible women.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results